Table of Contents Author Guidelines Submit a Manuscript
International Journal of Polymer Science
Volume 2015, Article ID 938594, 16 pages
http://dx.doi.org/10.1155/2015/938594
Research Article

Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Etodolac

1Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 22452, Riyadh 11495, Saudi Arabia
2Department of Pharmaceutics, National Organization for Drug Control and Research, P.O. Box 35521, Giza, Egypt
3Department of Pharmaceutics, Faculty of Pharmacy, Assiut University, P.O. Box 71515, Assiut, Egypt
4Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
5Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, P.O. Box 21500, Alexandria, Egypt

Received 5 October 2014; Accepted 13 January 2015

Academic Editor: Alenka Vesel

Copyright © 2015 Samar A. Afifi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Merisko-Liversidge, G. G. Liversidge, and E. R. Cooper, “Nanosizing: a formulation approach for poorly-water-soluble compounds,” European Journal of Pharmaceutical Sciences, vol. 18, no. 2, pp. 113–120, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. R. H. Müller and K. Peters, “Nanosuspensions for the formulation of poorly soluble drugs. I. Preparation by a size-reduction technique,” International Journal of Pharmaceutics, vol. 160, no. 2, pp. 229–237, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. K. R. Vandana, Y. Prasanna Raju, V. Harini Chowdary, M. Sushma, and N. Vijay Kumar, “An overview on in situ micronization technique—an emerging novel concept in advanced drug delivery,” Saudi Pharmaceutical Journal, vol. 22, no. 4, pp. 283–289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. A. K. Nayak and P. P. Panigrahi, “Solubility enhancement of etoricoxib by cosolvency approach,” ISRN Physical Chemistry, vol. 2012, Article ID 820653, 5 pages, 2012. View at Publisher · View at Google Scholar
  5. S. Sinha, M. Ali, S. Baboota, A. Ahuja, A. Kumar, and J. Ali, “Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir,” AAPS PharmSciTech, vol. 11, no. 2, pp. 518–527, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. K. T. Savjani, A. K. Gajjar, and J. K. Savjani, “Drug solubility: importance and enhancement techniques,” ISRN Pharmaceutics, vol. 2012, Article ID 195727, 10 pages, 2012. View at Publisher · View at Google Scholar
  7. C. Jacobs, O. Kayser, and R. H. Müller, “Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 161–164, 2000. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Kocbek, S. Baumgartner, and J. Kristl, “Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs,” International Journal of Pharmaceutics, vol. 312, no. 1-2, pp. 179–186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Gao, G. Liu, J. Ma, X. Wang, L. Zhou, and X. Li, “Drug nanocrystals: in vivo performances,” Journal of Controlled Release, vol. 160, no. 3, pp. 418–430, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Yadav, S. Dhole, and P. Chavan, “Nanosuspension: a novel techniques in drug delivery system,” World Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 2, pp. 410–433, 2014. View at Google Scholar
  11. B. H. L. Böhm and R. H. Müller, “Lab-scale production unit design for nanosuspensions of sparingly soluble cytotoxic drugs,” Pharmaceutical Science and Technology Today, vol. 2, no. 8, pp. 336–339, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. V. B. Patravale, A. A. Date, and R. M. Kulkarni, “Nanosuspensions: a promising drug delivery strategy,” Journal of Pharmacy and Pharmacology, vol. 56, no. 7, pp. 827–840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. R. J. Hintz and K. C. Johnson, “The effect of particle size distribution on dissolution rate and oral absorption,” International Journal of Pharmaceutics, vol. 51, no. 1, pp. 9–17, 1989. View at Publisher · View at Google Scholar · View at Scopus
  14. B. E. Rabinow, “Nanosuspensions in drug delivery,” Nature Reviews Drug Discovery, vol. 3, no. 9, pp. 785–796, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Peters, S. Leitzke, J. E. Diederichs et al., “Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection,” Journal of Antimicrobial Chemotherapy, vol. 45, no. 1, pp. 77–83, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. M. J. Grau, O. Kayser, and R. H. Müller, “Nanosuspensions of poorly soluble drugs—reproducibility of small scale production,” International Journal of Pharmaceutics, vol. 196, no. 2, pp. 155–159, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Chingunpituk, “Nanosuspension technology for drug delivery,” Walailak Journal of Science and Technology, vol. 4, no. 2, pp. 139–153, 2007. View at Google Scholar
  18. X. Pu, J. Sun, M. Li, and Z. He, “Formulation of nanosuspensions as a new approach for the delivery of poorly soluble drugs,” Current Nanoscience, vol. 5, no. 4, pp. 417–427, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. P. Lakshmi and G. A. Kumar, “Nanosuspension technology: a review,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 2, no. 4, pp. 35–40, 2010. View at Google Scholar · View at Scopus
  20. G. G. Liversidge and P. Conzentino, “Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats,” International Journal of Pharmaceutics, vol. 125, no. 2, pp. 309–313, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Papdiwal, V. Pande, and K. Sagar, “Design and characterization of zaltoprofen nanosuspension by precipitation method,” Der Pharma Chemica, vol. 6, no. 3, p. 161, 2014. View at Google Scholar
  22. M. Kakran, N. G. Sahoo, I.-L. Tan, and L. Li, “Preparation of nanoparticles of poorly water-soluble antioxidant curcumin by antisolvent precipitation methods,” Journal of Nanoparticle Research, vol. 14, no. 3, article 757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Xia, P. Quan, H. Piao, S. Sun, Y. Yin, and F. Cui, “Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability,” European Journal of Pharmaceutical Sciences, vol. 40, no. 4, pp. 325–334, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. B. P. Sahu and M. K. Das, “Formulation, optimization, and in vitro/in vivo evaluation of furosemide nanosuspension for enhancement of its oral bioavailability,” Journal of Nanoparticle Research, vol. 16, no. 4, article 2360, 2014. View at Publisher · View at Google Scholar · View at Scopus
  25. M. R. Bhalekar, P. G. Upadhaya, S. Reddy, S. J. Kshirsagar, and A. R. Madgulkar, “Formulation and evaluation of acyclovir nanosuspension for enhancement of oral bioavailability,” Asian Journal of Pharmaceutics, vol. 8, no. 2, p. 110, 2014. View at Publisher · View at Google Scholar
  26. A. Rezaei Mokarram, A. Kebriaee zadeh, M. Keshavarz, A. Ahmadi, and B. Mohtat, “Preparation and in-vitro evaluation of indomethacin nanoparticles,” DARU, vol. 18, no. 3, pp. 185–192, 2010. View at Google Scholar · View at Scopus
  27. J. A. Balfour and M. M.-T. Buckley, “Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatoid diseases and pain states,” Drugs, vol. 42, no. 2, pp. 274–299, 1991. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Talari, J. Varshosaz, S. A. Mostafavi, and A. Nokhodchi, “Gliclazide microcrystals prepared by two methods of in situ micronization: pharmacokinetic studies in diabetic and normal rats,” AAPS PharmSciTech, vol. 11, no. 2, pp. 786–792, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. W. Martindale, Martindale: The Extra Pharmacopoeia, Rittenhouse Book Distributors, 1996.
  30. A. Maccagno, E. di Giorgio, and A. Romanowicz, “Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout,” Current Medical Research and Opinion, vol. 12, no. 7, pp. 423–429, 1991. View at Publisher · View at Google Scholar · View at Scopus
  31. J. F. Mullane, “Etodolac for treatment of gout,” Google Patents, 1987.
  32. A. Okamoto, T. Shirakawa, T. Bito et al., “Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells In Vitro and In Vivo,” Urology, vol. 71, no. 1, pp. 156–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Tsuneoka, Y. Tajima, A. Kitazato et al., “Chemopreventative effect of a cyclooxygenase-2-specific inhibitor (etodolac) on chemically induced biliary carcinogenesis in hamsters,” Carcinogenesis, vol. 26, no. 2, pp. 465–469, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Glaser, “Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (Lodine),” in Side Effects of Anti-Inflammatory Drugs IV, pp. 211–221, Springer, Berlin, Germany, 1997. View at Google Scholar
  35. J.-M. Shi, S.-G. Lai, C.-J. Xu, G.-L. Duan, and D. Li, “Pharmacokinetic difference between S-(+)- and R-(−)-etodolac in rats,” Acta Pharmacologica Sinica, vol. 25, no. 8, pp. 996–999, 2004. View at Google Scholar · View at Scopus
  36. L. X. Yu, G. L. Amidon, J. E. Polli et al., “Biopharmaceutics classification system: the scientific basis for biowaiver extensions,” Pharmaceutical Research, vol. 19, no. 7, pp. 921–925, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. Y. Naito, H. Matsuda, K. Shimomura, K. Kurihara, K. Tochigi, and K. Tomono, “Measurement and correlation of solubilities of the poorly water-soluble pharmaceutical compound etodolac by addition of co-solvents,” Fluid Phase Equilibria, vol. 357, no. 2, pp. 43–49, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. L. S. Taylor and G. Zografi, “Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions,” Pharmaceutical Research, vol. 14, no. 12, pp. 1691–1698, 1997. View at Publisher · View at Google Scholar · View at Scopus
  39. B. Gorain, H. Choudhury, U. Nandi, A. Das, S. Dan, and T. K. Pal, “Development and validation of an HPLC method for simultaneous detection and quantification of paracetamol and etodolac in human plasma and its application to a pharmacokinetic study,” Journal of AOAC International, vol. 96, no. 3, pp. 573–579, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. J. G. Wagner and E. Nelson, “Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug,” Journal of Pharmaceutical Sciences, vol. 53, no. 11, pp. 1392–1403, 1964. View at Publisher · View at Google Scholar · View at Scopus
  41. D. Perrier and M. Gibaldi, Pharmacokinetics, 2nd edition, 1982.
  42. B. Sanford and B. Charles, Pharmaceutical Statistics: Practical and Clinical Applications, 4th edition, 2004.
  43. S. Kumar and D. J. Burgess, “Nanosuspensions,” in Long Acting Injections and Implants, pp. 239–261, Springer, 2012. View at Publisher · View at Google Scholar
  44. Y. Dong, W. K. Ng, S. Shen, S. Kim, and R. B. H. Tan, “Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation,” International Journal of Pharmaceutics, vol. 375, no. 1-2, pp. 84–88, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. L. Peltonen and J. Hirvonen, “Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods,” Journal of Pharmacy and Pharmacology, vol. 62, no. 11, pp. 1569–1579, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. P. R. Mishra, L. A. Shaal, R. H. Müller, and C. M. Keck, “Production and characterization of Hesperetin nanosuspensions for dermal delivery,” International Journal of Pharmaceutics, vol. 371, no. 1-2, pp. 182–189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. D. J. Patel, J. K. Patel, and V. M. Pandya, “Improvement in the dissolution of poorly water soluble drug using media milling technique,” Thai Journal of Pharmaceutical Sciences, vol. 34, no. 4, pp. 155–164, 2010. View at Google Scholar · View at Scopus
  48. Z. Zhu, K. Margulis-Goshen, S. Magdassi, Y. Talmon, and C. W. Macosko, “Polyelectrolyte stabilized drug nanoparticles via flash nanoprecipitation: a model study with beta-carotene,” Journal of Pharmaceutical Sciences, vol. 99, no. 10, pp. 4295–4306, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. E. Che, X. Zheng, C. Sun, D. Chang, T. Jiang, and S. Wang, “Drug nanocrystals: a state of the art formulation strategy for preparing the poorly water-soluble drugs,” Asian Journal of Pharmaceutical Sciences, vol. 7, no. 2, pp. 85–95, 2012. View at Google Scholar · View at Scopus
  50. Y. Chen, J. Liu, X. Yang, X. Zhao, and H. Xu, “Oleanolic acid nanosuspensions: preparation, in-vitro characterization and enhanced hepatoprotective effect,” Journal of Pharmacy and Pharmacology, vol. 57, no. 2, pp. 259–264, 2005. View at Publisher · View at Google Scholar · View at Scopus
  51. B. P. Sahu and M. K. Das, “Preparation and in vitro/in vivo evaluation of felodipine nanosuspension,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 39, no. 3, pp. 183–193, 2014. View at Publisher · View at Google Scholar · View at Scopus
  52. L. Wu, J. Zhang, and W. Watanabe, “Physical and chemical stability of drug nanoparticles,” Advanced Drug Delivery Reviews, vol. 63, no. 6, pp. 456–469, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Pardeike, D. M. Strohmeier, N. Schrödl et al., “Nanosuspensions as advanced printing ink for accurate dosing of poorly soluble drugs in personalized medicines,” International Journal of Pharmaceutics, vol. 420, no. 1, pp. 93–100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Rawat and S. Jain, “Enhancement of intestinal absorption of few cox-2 inhibitors through interaction with β-cyclodextrin,” Indian Journal of Pharmaceutical Sciences, vol. 69, no. 4, pp. 529–534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. S.-Y. Lin and Y.-H. Kao, “Solid particulates of drug-β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique,” International Journal of Pharmaceutics, vol. 56, no. 3, pp. 249–259, 1989. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Guyot, F. Fawaz, J. Bildet, F. Bonini, and A.-M. Lagueny, “Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions,” International Journal of Pharmaceutics, vol. 123, no. 1, pp. 53–63, 1995. View at Publisher · View at Google Scholar · View at Scopus
  57. N. S. Barakat, “Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation,” Journal of Pharmacy and Pharmacology, vol. 62, no. 2, pp. 173–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Jacobs and R. H. Müller, “Production and characterization of a budesonide nanosuspension for pulmonary administration,” Pharmaceutical Research, vol. 19, no. 2, pp. 189–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Radtke, “Pure drug nanoparticles for the formulation of poorly soluble drugs,” New Drugs, vol. 3, pp. 62–68, 2001. View at Google Scholar
  60. A. Lamprecht, U. Schäfer, and C.-M. Lehr, “Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa,” Pharmaceutical Research, vol. 18, no. 6, pp. 788–793, 2001. View at Publisher · View at Google Scholar · View at Scopus